Multicancer early detection: Can we screen for what we can't treat?
An FDA advisory panel has supported the clinical utility of multicancer early detection (MCED) tests, marking a potential shift in cancer screening paradigms.
Breast cancer home injections: Convenient for patients, complex for insurers
Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.
Multicancer tests: Can we screen without knowing the outcome?
An FDA panel recently reviewed multicancer early detection tests, highlighting significant data gaps regarding their clinical utility and impact on patient outcomes.
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Chemo hair loss: Why some patients feel it more deeply
Why are we still treating cancer prevention as adjunctive care?
Lung cancer in never smokers: The 60x risk factor you might be missing
Brain metastases: Why less radiation, more often, improves outcomes
Salivary gland cancer: Is HER2-low the new HER2-positive?
MASH: Why diabetes management now demands a liver-first approach?
Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.
Why primary sclerosing cholangitis remains a therapeutic graveyard
Despite numerous attempts, no disease-modifying therapy has succeeded in primary sclerosing cholangitis, leaving transplant as the only definitive treatment.
ACLF: Why G-CSF works for some, but fails others
Specific immune cell populations and inflammatory markers predict G-CSF treatment response and mortality in acute-on-chronic liver failure, a GRAFT sub-study shows.
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Liver disease: Is coffee a daily dose of prevention?
Seladelpar and elafibranor: second-line options for PBC
Peripheral arterial disease: Why early detection still eludes us
Peripheral arterial disease often goes undiagnosed until advanced stages, leading to preventable complications. Early detection is critical for improving patient outcomes.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.
GLP-1s: Is eligibility missing half your high-risk patients?
A 313,000-person Danish and UK analysis finds people with a BMI of 25-26.9, currently ineligible for GLP-1 receptor agonists, have coronary heart disease risk matching those who do qualify, if they also carry elevated remnant cholesterol or inflammation.
Tactical athletes need more than a sports physical
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Endocarditis: Why fixed-dose ampicillin often misses the mark
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Evolocumab: Is LDL-C reduction finally translating to lives saved?
Hypertension: Do shorter wall squats work as well for older women?
Bariatric surgery: The hidden hernia risk you're missing
Up to 20% of bariatric surgery candidates present with pre-existing ventral hernias, a significant comorbidity often overlooked in surgical planning.
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Eloralintide combined with tirzepatide cut body weight by up to 23.3% at 48 weeks in adults with obesity and type 2 diabetes, phase 2b data show.
CBL-514: Is visceral fat reduction the real story?
CBL-514 reduced visceral fat volume by 10.45% versus a 11.76% rise on placebo in a 40-person MRI subgroup, but the weight regain claim rests on rat data.
Type 1 diabetes screening: Why one protocol worked across 8 nations
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Marathon running with type 1 diabetes: Is it finally safe?
Survodutide: Is 9.8% weight loss enough for its GI cost?
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Tau hyperphosphorylation impairs cooperative binding to microtubules and disrupts lysosome trafficking in neurons, mimicking tau knockout effects.
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Spike sorting: Is your 'black box' holding back neural insights?
Understanding the intricate process of spike sorting is essential for interpreting neural recordings. A modular approach promises greater transparency and adaptability in this complex analytical task.
Fibromyalgia: Is the pain real if the tissue damage isn't?
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
Lifelong odor sensitivity: What early exposure means for your patients?
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
Routine childhood vaccines: Less coverage means more than just infections
Can mice learn to control their own brains? A new neurofeedback system
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
AdvertisementAdvertisementAdvertisement
• Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEUEG Week 2026 • Barcelona, ES • Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
Advertisement
BarcelonaOct 17 – 20 2026Get on-site reporting the moment it publishes.
BarcelonaAttending UEG Week 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
